UDENYCA® is the #1 prescribed pegfilgrastim prefilled syringe*1

An FDA-approved biosimilar to Neulasta® (pegfilgrastim)

UDENYCA® offers cost savings, reliable manufacturing, patient support, and more.
See why UDENYCA® is the #1 prescribed pegfilgrastim prefilled syringe (PFS) in the video below.

Video Play Button
Atom Icon
Proving the value
of biosimilars
UDENYCA® delivers high-quality treatment and the reliable outcomes you expect, but with 33% cost savings per dose.†2
LEARN MORE
Badge Icon
High-quality
treatment
UDENYCA® was confirmed to be highly similar to Neulasta®, with no clinically meaningful differences.3-5
LEARN MORE
Syringe Icon
Dosing & administration
UDENYCA® is dosed and administered identically to Neulasta® PFS.3
LEARN MORE
Building Icon
Manufacturing & distribution
UDENYCA® is proudly manufactured in the USA.5
LEARN MORE

Biosimilars Offer Choice Without Compromise

Biosimilars are safe, effective, and affordable alternatives to existing brand biologics. At Coherus BioSciences, we’re committed to ensuring patient access to biologics through high-quality, high-value biosimilars.

LEARN MORE
FDA Approved - UDENYCA<sup>®</sup> pegfilgrastim-cbqv

Comprehensive patient support services

Coherus COMPLETE provides a suite of patient support services, programs, and industry-leading electronic services designed to assist with patient access.

LEARN MORE
$0

Out-of-pocket (OOP) cost for each UDENYCA® dose*

*Must be prescribed UDENYCA® (pegfilgrastim-cbqv) for a medically appropriate use. Must have commercial health insurance that covers the medication costs of UDENYCA®. Must not be covered by any federal, state, or government-funded healthcare program, such as Medicare, Medicaid, Medicare Advantage, Medicare Part D, Veterans Affairs, the Department of Defense, or TRICARE. Must not seek co-pay assistance amount received from Coherus from any third-party payers, including flexible spending accounts or healthcare savings accounts.

Note: The Coherus COMPLETE Co-Pay Assistance Program covers ONLY the cost of UDENYCA® and does not cover any administration or office visit costs.

* As of January 2021, the pegfilgrastim prefilled syringe (PFS) marketplace includes ZIEXTENZO® (pegfilgrastim-bmez), Fulphila® (pegfilgrastim-jmdb), and Neulasta® (pegfilgrastim).

Based on wholesale acquisition cost (WAC). WAC does not necessarily reflect actual prices paid by consumers, pharmacies, or third-party payers. UDENYCA® WAC of $4175 per prefilled syringe vs Neulasta® WAC of $6231 per prefilled syringe.

References: 1. IQVIA Monthly National Sales Perspective Data. 2020. 2. First Databank, Inc. Pricing Compendia. 3. UDENYCA® (pegfilgrastim-cbqv) package insert. Redwood City, CA: Coherus BioSciences, Inc.; 2019. 4. Neulasta® (pegfilgrastim) package insert. Thousand Oaks, CA: Amgen Inc.; 2020. 5. Data on file. Coherus BioSciences, Inc.; 2021.